Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Snyder

Neurology Jacksonville Beach, FL Medical Doctor

NPI 1750378311 CMS profile 34184

1370 13Th Ave S Ste 215, Jacksonville Beach, FL 32250

Open in the dashboard

General payments

$182,093

599 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Snyder of Jacksonville Beach, FL is reported in the CMS Open Payments database as having received $182,093 across 599 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $252 11
2024 General $752 27
2023 General $594 14
2022 General $29,026 78
2021 General $29,922 122
2020 General $53,896 156
2019 General $67,651 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Snyder
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Thomas Snyder were reported at $252. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Thomas Snyder Neurology median Middle half National median
2019 $67,651 $474 $118–$2,177 $163
2020 $53,896 $367 $82–$2,309 $114
2021 $29,922 $438 $104–$2,547 $132
2022 $29,026 $442 $103–$2,388 $149
2023 $594 $464 $119–$2,312 $160
2024 $752 $468 $119–$2,323 $164
2025 $252 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $64,285 127 payments
  2. Genentech USA, Inc. $29,960 68 payments
  3. EMD Serono, Inc. $23,464 84 payments
  4. Celgene Corporation $20,847 38 payments
  5. E.R. Squibb & Sons, L.L.C. $15,946 16 payments
  6. Genzyme Corporation $13,929 39 payments
  7. Teva Pharmaceuticals USA, Inc. $8,264 59 payments
  8. Janssen Pharmaceuticals, Inc $1,275 7 payments
  9. Novartis Pharmaceuticals Corporation $776 25 payments
  10. Amgen Inc. $428 11 payments
  11. Other $2,920 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $123,110 64 payments
  2. Consulting Fee $36,687 14 payments
  3. Food and Beverage $13,440 462 payments
  4. Travel and Lodging $8,513 54 payments
  5. Education $343 5 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $36,524 51 payments
  2. TYSABRI $35,732 76 payments
  3. OCREVUS $27,832 65 payments
  4. Mavenclad Neurology $17,463 35 payments
  5. TECFIDERA $17,192 41 payments
  6. AUBAGIO $13,215 20 payments
  7. VUMERITY $13,055 36 payments
  8. COPAXONE $6,396 6 payments
  9. Mavenclad Neurology $4,219 15 payments
  10. Enspryng $2,223 8 payments
  11. Other $7,049 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$70,894

Medicare's payments for the services billed

Medicare patients

203

Average age 74

Services billed

592

125 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Depression 34%
Diabetes 30%
Chronic kidney disease 26%
Atrial fibrillation 25%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $75
$75 — —
VALTOCO
  • Neurelis, Inc. $46
$46 — —
EMGALITY
  • Lilly USA, LLC $43
$43 — —
VYVGART Hytrulo
  • ARGENX US, INC. $32
$32 — —
Ocrevus Zunovo
  • Genentech USA, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

599 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record